AOTI Inc. (ticker: -AOTI), the wound care medical technology company listed on the London Stock Exchange, has disclosed that three senior executives acquired common shares on 4 November 2026 through its Employee Share Purchase Plan (ESPP). The purchases were made by CSC Global on behalf of Chief Executive Officer Dr. Mike Griffiths, Chief Financial Officer Jayesh Pankhania, and Chief Operating Officer Anthony Moffatt. The transaction represents a routine but notable insider acquisition, with all three persons discharging managerial responsibilities (PDMRs) participating simultaneously at the same share price.

Key Points

  • AOTI Inc. (-AOTI), a wound care medical technology company headquartered in Oceanside, California and Galway, Ireland
  • CEO, CFO, and COO each purchased common shares at £1.350p per share on 4 November 2026 via the company's ESPP
  • Post-purchase shareholdings: Dr. Griffiths holds 6,789,637 shares (6.38%); Pankhania holds 407,121 shares (0.38%); Moffatt holds 1,182,487 shares (1.11%)
  • Investors may watch for further ESPP participation disclosures and commercial progress of the TWO2® therapy platform

CEO, CFO, and COO Each Purchase AOTI Common Shares at £1.350p via ESPP Trustee CSC Global

All three purchases were executed by CSC Global, operating through CSC Employee Benefit Trustee (Jersey) Limited and CSC Employee Benefit Services (Jersey) Limited, acting as trustee of the ESPP. Dr. Mike Griffiths acquired 665 shares, Jayesh Pankhania acquired 661 shares, and Anthony Moffatt acquired 660 shares, each at a price of £1.350p per common share. The shares carry an ISIN of US03690C1027 and a nominal value of $0.00001 each. Under the ESPP structure, participating employees make regular payroll contributions that are used to fund share acquisitions on their behalf, as the announcement states.

Post-Purchase Shareholding Stakes for AOTI's Senior Leadership After 4 November Transactions

Following the transactions, Dr. Griffiths holds 6,789,637 common shares, representing 6.38% of AOTI's issued share capital. Jayesh Pankhania's resulting stake stands at 407,121 shares, equating to 0.38% of the issued share capital, while Anthony Moffatt holds 1,182,487 shares, or 1.11%. The simultaneous participation of all three PDMRs through a structured payroll-contribution mechanism may indicate ongoing alignment between senior management's personal financial interests and the company's long-term performance, though the announcement does not offer any management commentary on strategic intent.

AOTI's Patented TWO2® Wound Oxygen Therapy Holds Regulatory Clearance Across Multiple Global Markets

Founded in 2006 and operating from Oceanside, California and Galway, Ireland, AOTI Inc. develops outcome-based care solutions targeting severe and chronic wounds, including Diabetic Foot Ulcers (DFUs). Its flagship TWO2® Topical Wound Oxygen therapy has received regulatory clearance from the FDA, CE Mark, MHRA, Health Canada, China's NMPA, Australia's TGA, and Saudi Arabia. The announcement notes that TWO2® has also recently received positive coverage recommendations from Germany's G-BA and the UK's NICE, developments that could support broader reimbursement and commercial adoption across two significant healthcare markets.